Clinical Trial Update: A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical study of YTS109 cell therapy for refractory autoimmune diseases is currently recruiting. The trial will evaluate safety and feasibility across …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antineutrophil Cytoplasmic Antibody-associated Vasculitis
• Antiphospholipid Syndrome
• Inflammatory Myopathy
• Lupus Nephritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• YTS109 cell therapy (YTS109)

Snippet

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. | Conditions: Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Status: RECRUITING